Research Topics
Genomes and GenesSpecies | Wolfgang A WeberSummaryAffiliation: Klinikum rechts der Isar Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imagingW A Weber
Departments of Nuclear Medicine, Surgery, Pathology, Radiology, and Medical Statistics, Technische Universitat Munchen, Munchen, Germany
J Clin Oncol 19:3058-65. 2001..This study evaluates whether positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may predict response early in the course of therapy...- Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose useWolfgang A Weber
Nuklearmedizinische Klinik, Klinikum rechts der Isar, Ismaning Strabetae 22, 81675 Munchen, Germany
J Clin Oncol 21:2651-7. 2003..To prospectively evaluate the use of positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) to predict response to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)... - Induction chemotherapy in Barrett cancer: influence on surgical risk and outcomeJoerg R Siewert
Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Ann Surg 246:624-8; discussion 628-31. 2007..To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer... - Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in manAmbros J Beer
Department of Nuclear Medicine, Lehrstuhl II für organische Chemie, Technische Universitat Munchen, Germany
Clin Cancer Res 12:3942-9. 2006..We have developed [18F]Galacto-RGD, a highly alpha(v)beta3-selective tracer for positron emission tomography (PET). Here, we show, in man, that the intensity of [18F]Galacto-RGD uptake correlates with alpha(v)beta3 expression... - Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junctionHinrich A Wieder
Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
J Nucl Med 46:2029-34. 2005..We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size... - Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junctionHinrich A Wieder
Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany
Eur J Nucl Med Mol Imaging 34:1925-32. 2007..To address this question we studied the time course of changes in tumor FDG-uptake in patients with locally advanced adenocarcinomas of the esophagogastric junction (AEG) treated with preoperative chemotherapy... - PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expressionAmbros J Beer
Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
J Nucl Med 47:763-9. 2006..18)F-Galacto-RGD is a new tracer for PET imaging of alpha v beta3, a receptor involved in a variety of pathologic processes including angiogenesis and metastasis. Our aim was to study the dosimetry of (18)F-galacto-RGD in humans... 
Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective studyKatja Ott
Department of Surgery, Technische Universitat Munchen, Munich, Germany
Clin Cancer Res 14:2012-8. 2008..The goal of the study was the definition of biologically different groups of patients prior to or early during induction therapy, with special emphasis on FDG non-avid tumors...- Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapyAnca L Grosu
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany
Int J Radiat Oncol Biol Phys 63:511-9. 2005..To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide... - Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomasSabrina T Astner
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Int J Radiat Oncol Biol Phys 72:1161-7. 2008.... - Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatmentHinrich A Wieder
Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, D 81675 Munich, Germany
J Clin Oncol 22:900-8. 2004.... - 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapyAnca Ligia Grosu
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Int J Radiat Oncol Biol Phys 66:339-44. 2006..To evaluate the role of 11C-methionine positron emission tomography (MET-PET) in target volume delineation for meningiomas and to determine the interobserver variability... - Positron emission tomography for radiation treatment planningAnca Ligia Grosu
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University, Munich, Germany
Strahlenther Onkol 181:483-99. 2005..To evaluate the impact of positron emission tomography (PET) on target volume delineation for radiation treatment planning... 
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGDRoland Haubner
Nuklearmedizinische Klinik und Poliklinik, Technische Universitat Munchen, Germany
PLoS Med 2:e70. 2005..We developed [(18)F]Galacto-RGD, a (18)F-labeled glycosylated alphavbeta3 antagonist, allowing monitoring of alphavbeta3 expression with positron emission tomography (PET)...- L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapyAnca Ligia Grosu
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Int J Radiat Oncol Biol Phys 63:64-74. 2005..The goal of this trial was to quantify the affect of MET-PET vs. with MRI in gross tumor volume definition for radiotherapy planning of high-grade gliomas... - Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardiaKatja Ott
Department of Surgery, Klinikum rechts der Isar, Technical University Munich, Ismaningerstrasse 22, D-81675 Munich, Germany
World J Surg 27:1035-9. 2003..This finding strengthens the hypothesis that AEG I and AEG II are two different tumor entities... - [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimatesRoland Haubner
Department of Nuclear Medicine, Technische Universitat Munchen, 81675 Munchen, Germany
Bioconjug Chem 15:61-9. 2004..2 GBq of [18F]flouride. Moreover, the fast excretion, the suitable metabolic stability and the low estimated radiation dose allow to evaluate this tracer in human studies... - Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGDBernd J Pichler
Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
J Nucl Med 46:184-9. 2005..We studied a hapten-induced delayed-type hypersensitivity reaction (DTHR) as a model for inflammatory processes, since DTHRs are involved in many human autoimmune disorders... - Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunctionNicolaus Andratschke
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Int J Radiat Oncol Biol Phys 64:1513-8. 2006..Although insulin-like growth factor-1 has previously been shown to protect the kidney, such an effect could not be demonstrated for EPO. The latter agent even increased the development of nephropathy... - Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junctionKatja Ott
Department of Surgery, Technische Universitaet Muenchen, Ismaningerstr 22, D 81675, Munich, Germany
J Clin Oncol 24:4692-8. 2006..The aim of this study was to prospectively validate these findings by using an a priori definition of metabolic response... - Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experienceAnca Ligia Grosu
Department of Radiation Oncology, Technical University Munich, Munich, Germany
Int J Radiat Oncol Biol Phys 56:1450-63. 2003..b) To validate the fully automatic CT/MET-PET image fusion technique with respect to accuracy and robustness. (c) To give a short glance at the clinical consequences for patients with brain tumors... - Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trialKatja Ott
Department of Surgery, Technische Universitä München, Munich, Germany
J Clin Oncol 21:4604-10. 2003..We prospectively evaluated the predictive value of therapy-induced reduction of tumor glucose use for subsequent response and patient survival in patients with gastric cancer treated by preoperative chemotherapy... - O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodesFriederike C Rau
Nuklearmedizinische Klinik der Technischen Universität München, Ismaninger Strasse 22, 81675 Munchen, Germany
Eur J Nucl Med Mol Imaging 29:1039-46. 2002..FET, in contrast, proved to be a specific tracer for differentiating between tumour-infiltrated and inflammatory LNs in the murine models studied... - Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cellsMartina Anton
Institute of Experimental Oncology, Technische Universitat Munchen, Germany
J Gene Med 6:119-26. 2004..Its expression is almost exclusively restricted to the sympathetic nervous system. In this study we evaluated whether the NET can be used as a reporter gene for non-invasive imaging of genetically modified cells with radiolabeled probes... - 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapyKen Herrmann
Division of Surgical Oncology, University of California at Los Angeles, 10833 Le Conte Avenue, Rm 54 140 CHS, Los Angeles, CA 90095, USA
Clin Cancer Res 18:2024-31. 2012..We prospectively evaluated whether 2[18F]fluoro-2-deoxy-d-glucose ((18)F-FDG)-PET/computed tomographic (CT) imaging after the initial cycle of neoadjuvant therapy could predict overall survival in these patients... - 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?Wolfgang A Weber
University of Freiburg, Freiburg, Germany
J Nucl Med 48:1580-2. 2007 - Monitoring cancer treatment with PET/CT: does it make a difference?Wolfgang A Weber
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California 90095, USA
J Nucl Med 48:36S-44S. 2007..The review concludes with an outlook on how PET/CT could make a difference in drug development and clinical management for patients... - Tumor cell metabolism imagingChristian Plathow
Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
J Nucl Med 49:43S-63S. 2008..In this review, we summarize recent data on the molecular mechanisms underlying the increased metabolic activity of cancer cells and discuss imaging techniques for studies of tumor glucose, lipid, and amino acid metabolism... - Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumorsHelen Su
Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
Eur J Nucl Med Mol Imaging 35:1089-99. 2008..In this study, we asked whether PET with [(18)F]gefitinib may be used to study noninvasively the pharmacokinetics of gefitinib in vivo and to image the EGFR status of cancer cells... - Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaMalik E Juweid
Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
J Clin Oncol 25:571-8. 2007..To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials... - Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture?Wolfgang A Weber
Clin Cancer Res 13:3105-6. 2007 - Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastomaLiu Hua Wei
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Clin Cancer Res 14:3416-26. 2008..The mechanisms underlying changes in metabolic activity were analyzed by measuring expression and functional activity of enzymes and transporters involved in the uptake of the studied imaging probes... - Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumorsMatthias R Benz
Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, California, USA
J Nucl Med 49:1038-46. 2008..Knowledge of the interobserver variability of quantitative parameters is important in sarcomas as these tumors are frequently large and demonstrate heterogeneous (18)F-FDG uptake... - PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trialFlorian Lordick
Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
Lancet Oncol 8:797-805. 2007..We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis... - Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imagingDerek W Bartlett
Chemical Engineering, California Institute of Technology, 1200 East California Boulevard, MC 210 41, Pasadena, CA 91125, USA
Proc Natl Acad Sci U S A 104:15549-54. 2007..Optimization of internalization may therefore be key for the development of effective nanoparticle-based targeted therapeutics... - Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugsWolfgang A Weber
Nuclear Medicine, University of Freiberg, Germany
Nat Clin Pract Oncol 5:44-54. 2008..Examples include imaging of the expression and inhibition of drug targets, noninvasive tissue pharmacokinetics, and early assessment of the tumor response... - Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanningWolfgang A Weber
Abteilung Nuklearmedizin, University of Freiburg, Hugstetterstrasse 56, 79106 Freiburg, Germany
Nat Clin Pract Oncol 5:160-70. 2008..In this Review we discuss the technical features of PET/CT, its economic aspects within the health-care system, and its role in diagnosis, staging, restaging and treatment monitoring as well as radiation planning in patients with cancer... - Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomasVladimir Evilevitch
Abteilung Nuklearmedizin University of Freiburg, Freiburg, Germany
Clin Cancer Res 14:715-20. 2008..The aim of this study was to prospectively evaluate whether positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) allows for a more accurate evaluation of histopathologic response... - Brown adipose tissue and nuclear medicine imagingWolfgang A Weber
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
J Nucl Med 45:1101-3. 2004 - Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PETChristian Waldherr
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
J Nucl Med 46:114-20. 2005.... - Monitoring response to treatment in patients utilizing PETNorbert E Avril
Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA
Radiol Clin North Am 43:189-204. 2005..In the future, PET imaging can also serve in the evaluation of new therapeutic agents, new experimental treatments, and specifically in monitoring clinical phase II studies... - Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancerJong-Ho Kim
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095-6942, USA
J Nucl Med 46:587-95. 2005..Due to its high failure rate, software fusion of independently acquired PET and CT studies cannot be considered to represent an alternative to in-line PET/CT... - Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT studyBenjamin S Halpern
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095-6942, USA
J Nucl Med 46:603-7. 2005..Thus, 5 min/bed position scans are sufficient for optimal lesion detection with LSO PET/CT in obese patients... - Use of PET for monitoring cancer therapy and for predicting outcomeWolfgang A Weber
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095 6942, USA
J Nucl Med 46:983-95. 2005..This review focuses on the practical aspects of (18)F-FDG PET for treatment monitoring and on how to perform a quantitative assessment of tumor (18)F-FDG uptake in clinical studies... - Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patientsAmbros J Beer
Department of Nuclear Medicine, , Germany
J Nucl Med 46:1333-41. 2005..Consequently, this tracer offers a new strategy for noninvasive monitoring of molecular processes and may supply helpful information for planning and controlling of therapeutic approaches targeting the alpha(v)beta(3) integrin... - Imaging of esophageal and gastric cancerWolfgang A Weber
Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany
Semin Oncol 31:530-41. 2004..Furthermore, quantitative measurements of tumor FDG uptake may predict histopathologic tumor response and patient outcome as early as 2 weeks after initiation of preoperative chemotherapy... - Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patientsBarbara J Fueger
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, CA 90095-6942, USA
Mol Imaging Biol 7:369-76. 2005..CONCLUSION: Integrated PET/CT only marginally improves the restaging accuracy over PET alone (p = 0.059) in breast cancer patients... - Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusionBenjamin S Halpern
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, AR 128 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095-6942, USA
Chest 128:2289-97. 2005..CONCLUSIONS: Integrated PET/CT compared with PET alone was associated with 26% points-greater overall diagnostic accuracy (p = 0.01). The software fusion method failed to provide acceptable co-registration in > 30% of the patients... - Molecular imaging in the development of cancer therapeuticsJohannes Czernin
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
Annu Rev Med 57:99-118. 2006..We conclude with a proposal to integrate molecular imaging into the drug development process... - Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomographyCecelia S Yap
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center/Nuclear Medicine, UCLA School of Medicine, AR-144 CHS, Los Angeles, CA 90095-6948, USA
Chest 129:393-401. 2006..Nevertheless, the correlation between FLT uptake and cellular proliferation suggests that future studies should evaluate the use of FLT-PET for monitoring treatment with cytostatic anticancer drugs... - Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancerNorbert Avril
University of Pittsburgh Medical Center, Division of Nuclear Medicine, 200 Lothrop St, Pittsburgh, PA, 15213, USA
J Clin Oncol 23:7445-53. 2005.... - Chaperoning drug development with PETWolfgang A Weber
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095-6942, USA
J Nucl Med 47:735-7. 2006 - Monitoring chemotherapy and radiotherapy of solid tumorsWolfgang A Weber
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095 6942, USA
Eur J Nucl Med Mol Imaging 33:27-37. 2006.... - Impact of animal handling on the results of 18F-FDG PET studies in miceBarbara J Fueger
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
J Nucl Med 47:999-1006. 2006..Isoflurane appears well suited for anesthesia of tumor-bearing mice, whereas ketamine/xylazine should be used with caution, as it may induce marked hyperglycemia... - Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphomaMartin Allen-Auerbach
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-6942 USA
Mol Imaging Biol 6:411-6. 2004..PET/CT correctly upstaged two and downstaged five patients. Overall staging was accurate in 93% with PET/CT and 84% with PET (P = 0.03). CONCLUSION: Lymphoma is staged with higher accuracy using PET/CT than PET alone... - Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomasMatthias R Benz
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA
J Nucl Med 49:1579-84. 2008..The aim of this study was to determine whether combined assessment of tumor volume and metabolic activity improves the accuracy of (18)F-FDG PET for predicting histopathologic tumor response in patients with soft-tissue sarcomas... - Anesthesia and other considerations for in vivo imaging of small animalsIsabel J Hildebrandt
Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at the University of California, Los Angeles, CA 90095 6942, USA
ILAR J 49:17-26. 2008..Reproducible experimental conditions require clear, consistent reporting, in the study design and throughout the experiment, of the animal strain and gender, fasting, anesthesia, and how often individual animals were imaged... - Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicityCarsten Nieder
Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
Anticancer Res 27:183-7. 2007.... - Positron emission tomography as an imaging biomarkerWolfgang A Weber
Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
J Clin Oncol 24:3282-92. 2006..However, further prospective and randomized validation of PET is still required before PET controlled chemotherapy can be used in clinical practice...